Abstract
Chimeric antigen receptor (CAR) T-cell immunotherapy has emerged as a potential option for the treatment of central nervous system (CNS) malignancies. Despite encouraging results in phase 1 clinical trials targeting glioblastoma (GBM), these efforts have not been as successful as those targeting hematological malignancies. In this chapter, we will summarize the current clinical experience in the field and will highlight the lessons learned from recent phase 1 clinical trials. We will also outline the obstacles that currently face the application of CAR T-cells for the treatment of CNS malignancies, as well as the various preclinical/clinical approaches aimed at overcoming them. This chapter is intended to help guide future endeavors that will move the field forward.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
